MediciNova Secures Patent for MN-166 in Glioblastoma Treatment with Anti-PD-1 Inhibitors
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
Image: Benzinga
MediciNova, Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering the use of MN-166 in combination with anti-PD-1 inhibitors for glioblastoma treatment. This patent strengthens the company's strategy in developing combination therapies for this aggressive cancer.
- 01The patent covers the use of MN-166 in combination with anti-PD-1 antibodies, addressing various treatment parameters such as dosing and administration.
- 02MN-166 is currently in late-stage clinical development for multiple conditions, including neurodegenerative diseases and glioblastoma.
- 03The allowed patent claims are expected to support ongoing clinical evaluations and enhance MediciNova's intellectual property portfolio.
- 04The patent is set to expire no earlier than September 2042, providing long-term protection for the combination therapy.
- 05Kazuko Matsuda, Chief Medical Officer, emphasized the importance of this patent in improving therapeutic outcomes for glioblastoma patients.
Advertisement
In-Article Ad
MediciNova, Inc., a biopharmaceutical company based in La Jolla, California, has announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application concerning the use of its compound ibudilast (MN-166) in combination with anti-PD-1 immune checkpoint inhibitors for glioblastoma treatment. This patent is expected to bolster the company's intellectual property position and support its strategy for developing combination therapies for this aggressive cancer type. The claims of the patent encompass various treatment parameters, including dosing regimens and routes of administration, which are crucial for evaluating the clinical utility of MN-166. The patent is anticipated to expire no earlier than September 2042, allowing for a significant period of protection. MN-166 is also being investigated for other conditions, such as ALS and progressive multiple sclerosis, highlighting its versatility in treating serious health issues. Kazuko Matsuda, the Chief Medical Officer of MediciNova, stated that this patent allowance is a significant step in addressing the unmet needs in glioblastoma treatment.
Advertisement
In-Article Ad
The patent's approval is expected to enhance MediciNova's ability to develop effective treatments for glioblastoma, a cancer with significant unmet medical needs.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of MN-166 in cancer treatment?
Connecting to poll...
Read the original article
Visit the source for the complete story.